Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial

Kahraman, Korhan; Şükür, Yavuz Emre; Ateş, Can; Taşkın, Salih; Çetinkaya, Şerife Esra; Tolunay, Harun Egemen; Özmen, Batuhan; Sönmezer, Murat; Berker, Bülent

doi:10.1007/s00404-014-3217-5

Cited by 34 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When looking at other parameters, CPA/EE showed significant reduction in hair diameter in all areas evaluated (chin, abdomen, mid-thigh, forearm and combined arms) at 12 months [45]. Greatest changes were seen in the abdomen (25%) and mid-thigh (20%) and objective results correlated with patients' own qualitative assessment of improvement in hirsutism at 12 months [45].…”

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 57%

“…Greatest changes were seen in the abdomen (25%) and mid-thigh (20%) and objective results correlated with patients' own qualitative assessment of improvement in hirsutism at 12 months [45]. Golland and Elstein [51] also reported correlation between objective and patient assessment.…”

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 65%

“…When treatment effect was assessed at 9 or 12 months, changes in hirsutism score ranged from 5% to 35% [44,45]. Creatsas et al [46], Luque-Ramierz et al [47], Lemay et al [48], Falsetti et al [49] described consistent reduction in hirsutism scores (F-G and mF-G) in all areas of the body.…”

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 99%

“…Kahraman et al [45] compared CPA/EE with drosperinone (DRSP)/EE and reported a significant difference in reduction in hirsutism score between the two, changes in mF-G score of À35% (À71 to 10) and À18% (À18 to 30) in women treated with CPA/EE and DRSP/EE, respectively.…”

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 99%

See 3 more Smart Citations

The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

Bitzer

Römer

Filho³

2017

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

Introduction: Hyperandrogenism affects approximately 10-20% of women of reproductive age. Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment. Women with abnormalities in androgen metabolism may have accompanying anovulation and/or polycystic ovary syndrome (PCOS), both of which have reproductive and metabolic implications if left untreated. Cyproterone acetate (CPA), combined with ethinylestradiol (EE), is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. Objective: To review the data on the efficacy and safety of CPA 2 mg/EE 35 lg for the treatment of hyperandrogenic skin symptoms in women. Methods: A non-systematic narrative review based on a literature search of the PubMed database. Results: Seventy-eight studies were identified. The majority of sufficiently powered studies show a high efficacy of CPA 2 mg/EE 35 lg in the treatment of severe acne and hirsutism. Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated. Additional benefits include cycle control and, in some women, improvement in mood and perception of body image. Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA). Conclusions: This review provides a comprehensive overview about the efficacy of CPA 2 mg/EE 35 lg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

show abstract

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 57%

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 65%

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 99%

Section: Efficacy In Hyperandrogenic Skin Symptoms Of Pcosmentioning

confidence: 99%

See 2 more Smart Citations

The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

Bitzer

Römer

Filho³

2017

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

“…A 2 mg CPA-t+EE-t tartalmazó készítmény acne kezelésére a drospirenont tartalmazó készítményekkel megegyező eredményessé-gű, de hirsut ismusban eredményessége jobb [43,44]. Alkalmazásánál lényeges tudni, hogy a CPA a VTE kialakulása szempontjából a magasabb kockázatot jelentő gesztagének közé tartozik.…”

Section: Az Antiandrogének Alkalmazásaunclassified

A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája

Gődény

Csenteri

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A polycystás ovarium szindróma a nők leggyakoribb endokrin és anyagcsere-betegsége. A különböző klinikai formá-ban jelentkező betegség kardinális tünetei közé tartoznak a hiperandrogén bőrtünetek és/vagy emelkedett szérum-androgénszintek, oligo-vagy amenorrhoea, anovuláció miatt kialakuló meddőség és esetenként a petefészek polycystás szerkezete. A szindróma kezelése függ a klinikai megjelenéstől, az életkortól, az alkalmazott diagnosztikus technológiák pontosságától, valamint attól, hogy mely kritériumrendszer alkalmazásával történt a diagnózis felállítá-sa. A bizonyítékon alapuló, megfelelően kiválasztott terápiás technológiával javul a kórkép kezelésének eredményes-sége, hatékonysága, a betegek biztonsága, életminősége és várható élettartama. A közlemény a rendelkezésre álló irodalmi adatok, elsősorban a legmagasabb szintű bizonyítékoknak tekinthető szisztematikus irodalmi áttekintések és metaanalízisek felhasználásával ismerteti a szindrómához társuló tünetek, az elhízás, a hyperandrogenismus, a vér-zészavarok, a meddőség és a lelki problémák kezelésének lehetőségeit. Orv. Hetil., 2015, 156(45), 1803-1815. Kulcsszavak: PCOS, klinikai tünetek, EBM, terápia Evidence-based therapy of polycystic ovarian syndromePolycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women. The heterogeneous endocrinopathy is characterized by clinical and/or biochemical hyperandrogenism, oligo-or amenorrhoea, anovulatory infertility, and polycystic ovarian morphology. The syndrome is often associated with obesity, hyperinsulinemia and adversely affects endocrine, metabolic, and cardiovascular health. The symptoms and complaint of the patients vary with age. To maximise health gain of the syndrome, adequate, evidence based effective, effi cient and safe treatment is necessary. This article summarises the highest available evidence provided by studies, meta-analysis and systematic reviews about the therapeutical possibilities for treating obesity, hyperandrogenism, menstrual abnormalities, infertility and psychological problems related to polycystic ovary syndrome ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések 2TDM = 2-es típusú diabetes mellitus; A = androsztendion; BMI = (body mass index) testtömegindex; CC = clomifen-citrát; CPA = ciproteron-acetát; CI = (confi dence interval) megbízhatósági tartomány, konfi denciaintervallum; DHEAS = dehidroepiandroszteron-szulfát; DHT = dihidro-tesztoszteron; DRSP = drospirenon; EBM = (evidence-based medicine) bizonyítékokon alapuló orvoslás; EE = etinil-ösztradiol; EE+CPA = etinil-ösztradiolt és ciproteron-acetátot tartalmazó kombinált készítmény; EE+DRSP = etinil-ösztradiolt és drospirenont tartalmazó kombinált készítmény; EMA = (European Medicines Agency) Európai Gyógyszerügynökség; FAI = (free androgen *A Debreceni Egyetem, Klinikai Központ, Szülészeti és Nőgyógyászati Klinika endokrin munkacsoportjának tagja.

show abstract

Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome

Fields

Trent

2016

JAMA Pediatr

View full text Add to dashboard Cite

Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial

Abstract: Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.

Cited by 34 publications

References 36 publications

The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája

Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About